DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/ee5b2e/dermatophytic_onyc) has announced the addition of GlobalData's new report "Dermatophytic Onychomycosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017" to their offering.
“Dermatophytic Onychomycosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017”
"Dermatophytic Onychomycosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017" is an essential source of information and analysis on the global dermatophytic onychomycosis market. The report identifies the key trends shaping and driving the global dermatophytic onychomycosis market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global dermatophytic onychomycosis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.
The analysis suggests that the global dermatophytic onychomycosis therapeutics market was valued at $2.1 billion in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 7% over the next seven years, to reach $3.4 billion by 2017. The steady growth is primarily attributed to the usage of generics and the entry of new molecule (AN-2690) as a topical therapy with a novel mechanism of action.
Scope:
- The report provides information on the key drivers and challenges of the Dermatophytic Onychomycosis Therapeutics market. Its scope includes:
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Dermatophytic Onychomycosis Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Dermatophytic Onychomycosis Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Dermatophytic Onychomycosis Therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements in Dermatophytic Onychomycosis Therapeutics market
The Report Will Enhance Your Decision Making Capability. It Will Allow You To:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Dermatophytic Onychomycosis Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Dermatophytic Onychomycosis Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Dermatophytic Onychomycosis Therapeutics market landscape? - Identify, understand and capitalize.
Companies Mentioned:
- Anacor Pharmaceuticals, Inc.
- Mayne Pharma Limited
- GlaxoSmithKline Plc.
- Hisamitsu Pharmaceutical Co. Inc.
- Promius Pharma LLC
- Celtic Pharmaceutical Holdings L.P.
- Valeant Pharmaceuticals International
- Kaken Pharmaceutical Co. Ltd.
- Nitric Biotherapeutics Inc.
- NanoBio Corporation
For more information visit http://www.researchandmarkets.com/research/ee5b2e/dermatophytic_onyc

